News|Articles|May 1, 2002

Revised rofecoxib labeling adds GI safety benefit, cardiovascular risk

Merck has issued revised labeling for its COX-2 inhibitor rofecoxib (Vioxx) that incorporate findings from the 8,000-patient VIGOR (Vioxx Gastrointestinal Outcomes Research) study.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.


Latest CME